Vor Biopharma (NYSE:VOR) Rating Reiterated by Wedbush

Vor Biopharma (NYSE:VOR)‘s stock had its “outperform” rating restated by research analysts at Wedbush in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $11.00 price objective on the stock.

Several other equities analysts have also issued reports on the company. Stifel Nicolaus reduced their target price on Vor Biopharma from $15.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, March 21st. Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 target price (down from $17.00) on shares of Vor Biopharma in a report on Thursday, March 21st. JMP Securities reaffirmed a “market outperform” rating and issued a $12.00 target price on shares of Vor Biopharma in a report on Friday, March 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $17.50 target price on shares of Vor Biopharma in a report on Thursday, March 21st. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $13.50.

Vor Biopharma Stock Performance

VOR stock opened at $1.74 on Tuesday. The company has a market capitalization of $118.70 million, a P/E ratio of -0.99 and a beta of -0.36. Vor Biopharma has a 52-week low of $1.62 and a 52-week high of $5.70. The business has a 50-day simple moving average of $2.03 and a two-hundred day simple moving average of $2.11.

Vor Biopharma (NYSE:VOR) last released its quarterly earnings results on Wednesday, March 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.10. As a group, sell-side analysts forecast that Vor Biopharma will post -1.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vor Biopharma

A hedge fund recently raised its stake in Vor Biopharma stock. Exchange Traded Concepts LLC boosted its position in Vor Biopharma Inc. (NYSE:VOR) by 34.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 60,170 shares of the company’s stock after purchasing an additional 15,258 shares during the period. Exchange Traded Concepts LLC owned about 0.09% of Vor Biopharma worth $135,000 as of its most recent SEC filing. Institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.